VERV

Verve Therapeutics Inc

Add to Watchlist

Advanced Chart

5.460

-0.270(-4.710%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

5.730

Open

5.690

VWAP

5.54

Vol

2.14M

Mkt Cap

486.72M

Low

5.400

Amount

11.87M

EV/EBITDA(TTM)

Total Shares

83.97M

-13.49M

EV/OCF(TTM)

P/S(TTM)

15.01

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

9.38M

+64.63%

-0.656

+11.15%

4.79M

-28.47%

-0.689

+16.85%

4.66M

-32.14%

-0.706

+19.64%

Estimates Revision

The market is revising Upward the revenue expectations for Verve Therapeutics, Inc. (VERV) for FY2025, with the revenue forecasts being adjusted by 80.15% over the past three months. During the same period, the stock price has changed by -26.32%.

Revenue Estimates for FY2025

Revise Upward

+80.15%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-8.61%

In Past 3 Month

Stock Price

Go Down

-26.32%

In Past 3 Month

10 Analyst Rating

362.45% Upside

Wall Street analysts forecast VERV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERV is 25.25 USD with a low forecast of 15.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

362.45% Upside

Current: 5.460

Low

15.00

Averages

25.25

High

39.00

362.45% Upside

Current: 5.460

Low

15.00

Averages

25.25

High

39.00

Canaccord Genuity

Whitney Ijem

Strong Buy

Maintains

$32 → $39

2025-04-15

Reason

Canaccord Genuity

Whitney Ijem

Price Target

$32 → $39

2025-04-15

Maintains

Strong Buy

Reason

Canaccord raised the firm's price target on Verve Therapeutics to $39 from $32 and keeps a Buy rating on the shares. The firm said Verve's initial Ph1b data for VERVE-102 knocked it out of the park on both safety and efficacy and accomplished everything it sought to do, and more. Canaccord increased our POS for the program from 50% to 70% and noted the company will report updated data including higher dose data, at a major medical meeting in 2H25.

Guggenheim

Etzer Darout

Strong Buy

Maintains

$18 → $24

2025-04-15

Reason

Guggenheim

Etzer Darout

Price Target

$18 → $24

2025-04-15

Maintains

Strong Buy

Reason

Guggenheim raised the firm's price target on Verve Therapeutics to $24 from $18 and keeps a Buy rating on the shares, arguing that the top-line Heart-2 Phase 1b data for VERVE-102 "provided a strikingly clean win." Following the data, the firm is increasing its view on the odds of success to 75% from 60%, the analyst noted.

Cantor Fitzgerald

Rick Bienkowski

Hold

Buy

Upgrades

n/a

2025-04-15

Reason

Cantor Fitzgerald

Rick Bienkowski

Price Target

n/a

2025-04-15

Upgrades

Hold

Buy

Reason

Cantor Fitzgerald upgraded Verve Therapeutics to Overweight from Neutral.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Maintains

$15 → $25

2025-04-14

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$15 → $25

2025-04-14

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$15

2025-03-25

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$15

2025-03-25

Reiterates

Strong Buy

Reason

Guggenheim

Seamus Fernandez

Strong Buy

Reiterates

n/a

2025-03-25

Reason

Guggenheim

Seamus Fernandez

Price Target

n/a

2025-03-25

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Verve Therapeutics Inc (VERV.O) is -2.16, compared to its 5-year average forward P/E of -7.54. For a more detailed relative valuation and DCF analysis to assess Verve Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.54

Current PE

-2.16

Overvalued PE

-0.55

Undervalued PE

-14.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.25

Current EV/EBITDA

-0.19

Overvalued EV/EBITDA

1.70

Undervalued EV/EBITDA

-12.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

322.30

Current PS

21.15

Overvalued PS

769.84

Undervalued PS

-125.23

Financials

Annual

Quarterly

FY2024Q4

YoY :

+154.28%

13.08M

Total Revenue

FY2024Q4

YoY :

+3.93%

-56.07M

Operating Profit

FY2024Q4

YoY :

+3.48%

-50.04M

Net Income after Tax

FY2024Q4

YoY :

-15.94%

-0.58

EPS - Diluted

FY2024Q4

YoY :

-1.48%

-42.23M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

-63.04%

-499.28

FCF Margin - %

FY2024Q4

YoY :

-59.30%

-382.53

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 3089.27% over the last month.

Sold

0-3

Months

99.8K

USD

3-6

Months

3.1K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

475.8K

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 253.89% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

65.2K

Volume

6-9

Months

0.0

Volume

0-12

Months

282.2K

Volume

Bought

0-3

0.0

Volume

Months

3-6

6.4M

Volume

Months

6-9

0.0

Volume

Months

0-12

1.8M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 3089.27% over the last month.

Sold

0-3

Months

99.8K

USD

3-6

Months

3.1K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

475.8K

USD

Months

VERV News & Events

Events Timeline

2025-04-14 (ET)

2025-04-14

07:05:31

Verve announces initial data from Heart-2 Phase 1b trial of VERVE-102

2025-04-11 (ET)

2025-04-11

07:03:49

Verve Therapeutics receives FDA Fast Track designation for VERVE-102

2025-03-31 (ET)

2025-03-31

09:32:22

BMO says Peter Marks resignation 'significant negative' for biotech

News

2.0

04-21Benzinga

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday

2.0

04-15Benzinga

Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday (CORRECTED)

2.0

04-15Benzinga

Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday

People Also Watch

CLW

Clearwater Paper Corp

Douyu International Holdings Ltd

Stoke Therapeutics Inc

Rayonier Advanced Materials Inc

Alerus Financial Corp

Senseonics Holdings Inc

MeiraGTx Holdings PLC

6.900

USD

+1.32%

FAQ

What is Verve Therapeutics Inc (VERV) stock price today?

The current price of VERV is 5.46 USD — it has decreased -4.71 % in the last trading day.

VERV

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

VERV News & Events

Events Timeline

News

People Also Watch

FAQ

What is Verve Therapeutics Inc (VERV) stock price today?

What is Verve Therapeutics Inc (VERV)'s business?

What is the price predicton of VERV Stock?

What is Verve Therapeutics Inc (VERV)'s revenue for the last quarter?

What is Verve Therapeutics Inc (VERV)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Verve Therapeutics Inc (VERV)'s fundamentals?

How many employees does Verve Therapeutics Inc (VERV). have?

What is Verve Therapeutics Inc (VERV) market cap?